1. De Oliveira GL, Guerra Junior AA, Godman B, Acurcio FA. Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert Rev Pharmacoecon Outcomes Res. 2017;17(2):109–19.
2. American Diabetes Association (ADA). Standards of medical care in diabetes. Position statement. Diabetes Care. 2017;40(1):S1–135.
3. German Institute for Quality and Efficency in Healthcare (IQWiG). Long-acting insulin analogues in the treatment of diabetes mellitus type 1: Executive Summary Commission No. A05-01. 2010. https://www.iqwig.de/en/projects_results/projects/drug_assessment/a05_01_long_acting_insulin_analogues_in_the_treatment_of_diabetes_mellitus_type_1.1197.html. Accessed 2 July 2017.
4. Souza ALC, de Acurcio AF, Junior AAG, do Nascimento RCRM, Godman B, Diniz LM. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12(1):19–32.
5. WHO. World Health Organisation. Review of the Evidence Comparing Insulin (Human or Animal) With Analogue Insulins. 18th Expert Committee on the Selection and Use of Essential Medicines. 1–51. 2011. http://www.who.int/selection_medicines/committees/expert/18/applications/Insulin_review.pdf. Accessed 6 June 2017.